Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-251-0005
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$387.29 million
Profitability
Miscellaneous
Employees804
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) released its quarterly earnings data on Wednesday, November, 6th. The medical equipment provider reported ($0.58) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.85) by $0.27. The medical equipment provider had revenue of $100.16 million for the quarter, compared to analyst estimates of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The business's quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) EPS. View Nevro's Earnings History.
When is Nevro's next earnings date?
What price target have analysts set for NVRO?
11 analysts have issued 12 month price targets for Nevro's shares. Their forecasts range from $65.00 to $115.00. On average, they anticipate Nevro's stock price to reach $88.64 in the next year. This suggests that the stock has a possible downside of 15.3%. View Analyst Price Targets for Nevro.
What is the consensus analysts' recommendation for Nevro?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.
What are Wall Street analysts saying about Nevro stock?
Here are some recent quotes from research analysts about Nevro stock:
- 1. According to Zacks Investment Research, "Nevro exited the second quarter on a weak note. The company’s domestic and international revenues deteriorated year over year. Loss per share widened on a year-over-year basis. Significant contraction in gross margin raises concern. Surge in operating expenses adds to the woes. The stock is overvalued at the moment. On the bright side, increased R&D expenses reflect focus on innovation. The guidance for 2019 is also promising. Management is further optimistic about the long-term prospects of the flagship Senza II platform, launched late last year. Nevro is also on track to launch its next product platform, Omnia, which is expected to lend the company a competitive edge in the near future. The stock has outperformed the industry over the past year." (8/13/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)
Has Nevro been receiving favorable news coverage?
News headlines about NVRO stock have been trending neutral on Monday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a news impact score of 0.3 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Nevro.
Are investors shorting Nevro?
Nevro saw a increase in short interest in October. As of October 15th, there was short interest totalling 3,880,000 shares, an increase of 25.6% from the September 15th total of 3,090,000 shares. Based on an average trading volume of 400,900 shares, the short-interest ratio is presently 9.7 days. Approximately 13.1% of the shares of the company are short sold. View Nevro's Current Options Chain.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), NuVasive (NUVA), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Cantel Medical (CMD), Glaukos (GKOS), Irhythm Technologies (IRTC) and Inspire Medical Systems (INSP).
What other stocks do shareholders of Nevro own?
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
- Mr. Patrick Schmitz, VP of Operations (Age 59)
- Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
- Mr. Doug Alleavitch, VP of Quality (Age 58)
- Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)
Who are Nevro's major shareholders?
Nevro's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (0.58%), California Public Employees Retirement System (0.18%), Tamarack Advisers LP (0.17%), Rhumbline Advisers (0.13%), First Trust Advisors LP (0.09%) and Rice Hall James & Associates LLC (0.08%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which institutional investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, SG Americas Securities LLC, Rice Hall James & Associates LLC, First Trust Advisors LP, Cambiar Investors LLC, Strs Ohio and Rhumbline Advisers. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.
Which institutional investors are buying Nevro stock?
NVRO stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Lisanti Capital Growth LLC, Tamarack Advisers LP, Creative Planning, BB&T Securities LLC, Oppenheimer Asset Management Inc. and Quest Capital Management Inc. ADV. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $104.63.
How big of a company is Nevro?
Nevro has a market capitalization of $3.24 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.
What is Nevro's official website?
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
